CTRL and COVID-19: A recent international randomized controlled clinical trial showed that the SARS-CoV-2 3-chymotrypsin-like protease (3CLpro) inhibitor PF-07321332 is orally bioavailable and highly effective in reducing the clinical severity of COVID-19.